- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01063946
A Study to Investigate the Disposition of Radio-labeled AVE8062 Compound Administered as a 30-minute IV Infusion to Patients With Advanced Solid Tumor
December 20, 2011 updated by: Sanofi
A Phase I, Open Label Study Investigating the Disposition of 25 mg/m² [14C]-AVE8062 (1.85 MBq, 50 µCi) Administered at Cycle 1 as a 30-minute Intravenous Infusion to Patients With Advanced Solid Tumors
Primary Objectives:
- To determine the excretion balance and systemic exposure of radioactivity after intravenous infusion of [14C]-AVE8062 to humans
- To determine the pharmacokinetics of AVE8062 and RPR258063 and their contribution to overall exposure
- To collect samples to determine the metabolic pathways of AVE8062 and identify the chemical structures of the main metabolites
Secondary Objective:
- To assess the safety profile of the drug
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The duration of the study for each patient will include approximately 4 weeks of a screening phase prior to first infusion of study drug, 21-day study treatment cycles and end of treatment visit.
The patient can continue treatment until disease progression, unacceptable toxicity, or the patient's refusal of further treatment.
Study Type
Interventional
Enrollment (Actual)
3
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Brussels, Belgium
- Sanofi-Aventis Administrative Office
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion criteria:
- Patients with advanced neoplastic disease that has become refractory to conventional treatment or for which no standard therapy exists.
- Age = or > 18 years
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
- Adequate hematological, hepatic and renal functions
Exclusion criteria:
- Poor metabolizers for CYP2C19, CYP2C9, CYP2D6 and polymorphic UGTs will be excluded from the study
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: [14C]-AVE8062
Single, 30 minute, intravenous infusion of 25 mg/m² of [14C]-AVE8062 containing 1.85 MBq (50µCi) at the first cycle, followed by subsequent administrations with non-radiolabelled AVE8062 in combination with cisplatin every 3 weeks, according to the investigator's judgment.
|
Pharmaceutical form:concentrate solution Route of administration: intravenous infusion |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percentage of radioactive dose excreted in urine, feces and expired air
Time Frame: 3 weeks (end of cycle 1) or 30 days after the first dose
|
3 weeks (end of cycle 1) or 30 days after the first dose
|
Concentration-time profiles and pharmacokinetic (PK) parameters of total radioactivity in whole blood and plasma; blood over plasma concentration ratios; Concentration-time profile and PK parameters of AVE8062 and RPR258063 in plasma
Time Frame: 3 weeks (end of cycle 1) or 30 days after the first dose
|
3 weeks (end of cycle 1) or 30 days after the first dose
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety assessment based on Adverse events reporting, laboratory tests according to the National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI-CTC) v3.0 grade scaling
Time Frame: 3 weeks (end of cycle 1) or 30 days after the first dose
|
3 weeks (end of cycle 1) or 30 days after the first dose
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2010
Primary Completion (Actual)
March 1, 2011
Study Completion (Actual)
September 1, 2011
Study Registration Dates
First Submitted
February 4, 2010
First Submitted That Met QC Criteria
February 4, 2010
First Posted (Estimate)
February 5, 2010
Study Record Updates
Last Update Posted (Estimate)
December 21, 2011
Last Update Submitted That Met QC Criteria
December 20, 2011
Last Verified
December 1, 2011
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BEX6587
- 2008-007824-24 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neoplasms, Malignant
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedMetastatic Malignant Neoplasm | Unresectable Malignant Neoplasm | Advanced Malignant NeoplasmUnited States
-
Lucid Lane, IncM.D. Anderson Cancer CenterRecruitingMalignant Solid Neoplasm | Malignant Thoracic Neoplasm | Malignant Head and Neck Neoplasm | Malignant Abdominal NeoplasmUnited States
-
National Cancer Institute (NCI)Active, not recruitingAdvanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedRecurrent Malignant Mesothelioma | Stage IA Malignant Mesothelioma | Stage IB Malignant Mesothelioma | Stage II Malignant Mesothelioma | Stage III Malignant Mesothelioma | Stage IV Malignant MesotheliomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingAdvanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Metastatic Malignant Neoplasm in the Liver | Metastatic Malignant Neoplasm in the LungUnited States
-
National Cancer Institute (NCI)RecruitingAdvanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States
-
National Cancer Institute (NCI)Active, not recruitingAdvanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States
-
National Cancer Institute (NCI)CompletedAdvanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Malignant Mesothelioma | Epithelial Mesothelioma | Sarcomatous Mesothelioma | Stage IA Malignant Mesothelioma | Stage IB Malignant Mesothelioma | Stage II Malignant Mesothelioma | Stage III Malignant Mesothelioma | Stage IV Malignant MesotheliomaUnited States
-
M.D. Anderson Cancer CenterActive, not recruitingRefractory Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States
Clinical Trials on Ombrabulin (AVE8062)
-
SanofiCompleted
-
SanofiCompletedNeoplasmsFrance, Italy, Switzerland
-
SanofiCompletedSarcomaBelgium, Hungary, United States, Brazil, France, India, Italy, Serbia, Spain, United Kingdom
-
SanofiCompletedNon-small Cell Lung CancerFrance, Romania, Poland, Croatia, Korea, Republic of, Italy, Chile, United States, Australia, Germany, Russian Federation, Serbia, Ukraine
-
SanofiCompleted
-
SanofiCompleted
-
SanofiCompleted
-
SanofiCompleted
-
SanofiCompletedOvarian Cancer RecurrentBelgium, Russian Federation, Poland, Spain, Czech Republic, United States, France, Germany, Italy, Ukraine
-
SanofiCompletedNeoplasms, MalignantFrance, United Kingdom, Italy